These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 31153581

  • 1. Prognosis assessment in metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors based on CT-texture analysis.
    Ekert K, Hinterleitner C, Horger M.
    Eur J Radiol; 2019 Jul; 116():98-105. PubMed ID: 31153581
    [Abstract] [Full Text] [Related]

  • 2. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK.
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [Abstract] [Full Text] [Related]

  • 3. Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy-Impact on clinical outcome.
    Meyer M, Ota H, Messiou C, Benson C, Henzler T, Mattonen SA, Marin D, Bartsch A, Schoenberg SO, Riedel RF, Hohenberger P.
    Int J Cancer; 2024 Dec 01; 155(11):2047-2057. PubMed ID: 39023303
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
    Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S.
    Cancer; 2018 Apr 01; 124(7):1449-1454. PubMed ID: 29315500
    [Abstract] [Full Text] [Related]

  • 5. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.
    Eur J Cancer; 2017 Nov 01; 86():226-232. PubMed ID: 29054076
    [Abstract] [Full Text] [Related]

  • 6. The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents.
    Betz M, Kopp HG, Spira D, Claussen CD, Horger M.
    Acta Radiol; 2013 Sep 01; 54(7):711-21. PubMed ID: 23761542
    [Abstract] [Full Text] [Related]

  • 7. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 01; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S.
    Cancer Treat Rev; 2012 Aug 01; 38(5):467-72. PubMed ID: 22035971
    [Abstract] [Full Text] [Related]

  • 10. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.
    Li J, Huang S, Zhu H, Shou C, Lin T, Yin X, Zhu Q, Sun D, Li X, Shen L, Li J, Kou Y, Zhou Y, Zhang B, Qian H, Yu J, Zhou Y, Tang L, Zhang X.
    Eur Radiol; 2024 Jun 01; 34(6):3659-3670. PubMed ID: 37947835
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the Relationships Between Computed Tomography Features, Pathological Findings, and Prognostic Risk Assessment in Gastrointestinal Stromal Tumors.
    Iannicelli E, Carbonetti F, Federici GF, Martini I, Caterino S, Pilozzi E, Panzuto F, Briani C, David V.
    J Comput Assist Tomogr; 2017 Jun 01; 41(2):271-278. PubMed ID: 27753723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.
    Rev Esp Med Nucl; 2008 Jun 01; 27(3):168-75. PubMed ID: 18570858
    [Abstract] [Full Text] [Related]

  • 14. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
    Chacón M, Eleta M, Espindola AR, Roca E, Méndez G, Rojo S, Pupareli C.
    Future Oncol; 2015 Jun 01; 11(6):953-64. PubMed ID: 25760976
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria.
    Meyer M, Hohenberger P, Apfaltrer P, Henzler T, Dinter DJ, Schoenberg SO, Fink C.
    Eur J Radiol; 2013 Jun 01; 82(6):923-8. PubMed ID: 23410905
    [Abstract] [Full Text] [Related]

  • 17. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C, Rutkowski P, Brzuszkiewicz K, Bylina E, Limon J, Siedlecki JA.
    Pol Przegl Chir; 2014 Jul 01; 86(7):325-32. PubMed ID: 25222580
    [Abstract] [Full Text] [Related]

  • 18. Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results.
    Schramm N, Schlemmer M, Englhart E, Hittinger M, Becker C, Reiser M, Berger F.
    Curr Pharm Biotechnol; 2011 Apr 01; 12(4):547-57. PubMed ID: 21342100
    [Abstract] [Full Text] [Related]

  • 19. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.
    J Clin Oncol; 2015 Dec 20; 33(36):4276-83. PubMed ID: 26573069
    [Abstract] [Full Text] [Related]

  • 20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.
    Am J Surg Pathol; 2009 Feb 20; 33(2):218-26. PubMed ID: 18830121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.